<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Neurosci</journal-id>
<journal-id journal-id-type="hwp">jneuro</journal-id>
<journal-id journal-id-type="pmc">jneurosci</journal-id>
<journal-id journal-id-type="publisher-id">J. Neurosci</journal-id>
<journal-title-group>
<journal-title>The Journal of Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="ppub">0270-6474</issn>
<issn pub-type="epub">1529-2401</issn>
<publisher>
<publisher-name>Society for Neuroscience</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28630251</article-id>
<article-id pub-id-type="pmc">5518418</article-id>
<article-id pub-id-type="publisher-id">0970-17</article-id>
<article-id pub-id-type="doi">10.1523/JNEUROSCI.0970-17.2017</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Articles</subject>
<subj-group>
<subject>Neurobiology of Disease</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Valnoctamide Inhibits Cytomegalovirus Infection in Developing Brain and Attenuates Neurobehavioral Dysfunctions and Brain Abnormalities</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0001-6898-7217</contrib-id>
<name>
<surname>Ornaghi</surname>
<given-names>Sara</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-5425-9785</contrib-id>
<name>
<surname>Hsieh</surname>
<given-names>Lawrence S.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0003-3496-3385</contrib-id>
<name>
<surname>Bordey</surname>
<given-names>Angélique</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vergani</surname>
<given-names>Patrizia</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Paidas</surname>
<given-names>Michael J.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>van den Pol</surname>
<given-names>Anthony N.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<aff id="aff1"><sup>1</sup>Department of Neurosurgery, and </aff>
<aff id="aff2"><sup>2</sup>Yale Women and Children's Center for Blood Disorders and Preeclampsia Advancement, Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut, 06520, </aff>
<aff id="aff3"><sup>3</sup>Ph.D. Program in Neuroscience, School of Medicine and Surgery, University of Milan-Bicocca, Monza 20900, Italy, </aff>
<aff id="aff4"><sup>4</sup>Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China, and </aff>
<aff id="aff5"><sup>5</sup>Department of Obstetrics and Gynecology, Foundation MBBM, San Gerardo Hospital, Monza 20900, Italy</aff>
</contrib-group>
<author-notes>
<corresp>Correspondence should be addressed to Anthony N. van den Pol,
<addr-line>Department of Neurosurgery, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520.</addr-line><email>anthony.vandenpol@yale.edu</email></corresp>
<fn fn-type="con">
<p>Author contributions: S.O. and A.N.v.d.P. designed research; S.O. and L.S.H. performed research; A.B., P.V., M.J.P., and A.N.v.d.P. contributed unpublished reagents/analytic tools; S.O. analyzed data; S.O. and A.N.v.d.P. wrote the paper.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>19</day>
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>19</day>
<month>1</month>
<year>2018</year>
</pub-date>
<!-- PMC Release delay is 6 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>37</volume>
<issue>29</issue>
<fpage>6877</fpage>
<lpage>6893</lpage>
<history>
<date date-type="received">
<day>11</day>
<month>4</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>25</day>
<month>5</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>31</day>
<month>5</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2017 the authors 0270-6474/17/376877-17$15.00/0</copyright-statement>
<copyright-year>2017</copyright-year>
</permissions>
<self-uri content-type="pdf" xlink:href="zns02917006877.pdf"></self-uri>
<abstract>
<p>Cytomegalovirus (CMV) is the most common infectious cause of brain defects and neurological dysfunction in developing human babies. Due to the teratogenicity and toxicity of available CMV antiviral agents, treatment options during early development are markedly limited. Valnoctamide (VCD), a neuroactive mood stabilizer with no known teratogenic activity, was recently demonstrated to have anti-CMV potential. However, it is not known whether this can be translated into an efficacious therapeutic effect to improve CMV-induced adverse neurological outcomes. Using multiple models of CMV infection in the developing mouse brain, we show that subcutaneous low-dose VCD suppresses CMV by reducing the level of virus available for entry into the brain and by acting directly within the brain to block virus replication and dispersal. VCD during the first 3 weeks of life restored timely acquisition of neurological milestones in neonatal male and female mice and rescued long-term motor and behavioral outcomes in juvenile male mice. CMV-mediated brain defects, including decreased brain size, cerebellar hypoplasia, and neuronal loss, were substantially attenuated by VCD. No adverse side effects on neurodevelopment of uninfected control mice receiving VCD were detected. Treatment of CMV-infected human fetal astrocytes with VCD reduced both viral infectivity and replication by blocking viral particle attachment to the cell, a mechanism that differs from available anti-CMV drugs. These data suggest that VCD during critical periods of neurodevelopment can effectively suppress CMV replication in the brain and safely improve both immediate and long-term neurological outcomes.</p>
<p><bold>SIGNIFICANCE STATEMENT</bold> Cytomegalovirus (CMV) can irreversibly damage the developing brain. No anti-CMV drugs are available for use during fetal development, and treatment during the neonatal period has substantial limitations. We studied the anti-CMV actions of valnoctamide (VCD), a psychiatric sedative that appears to lack teratogenicity and toxicity, in the newborn mouse brain, a developmental period that parallels that of an early second-trimester human fetus. In infected mice, subcutaneous VCD reaches the brain and suppresses viral replication within the CNS, rescuing the animals from CMV-induced brain defects and neurological problems. Treatment of uninfected control animals exerts no detectable adverse effects. VCD also blocks CMV replication in human fetal brain cells.</p>
</abstract>
<kwd-group>
<kwd>brain</kwd>
<kwd>cytomegalovirus</kwd>
<kwd>development</kwd>
<kwd>dysfunction</kwd>
<kwd>infection</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>